Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CICR-NAM for Induction and Maintenance Therapy in Ulcerative Colitis
NCT06488625Phase 3Recruiting
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Sep 2024
- Primary completion
- Oct 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of nicotinamide in ulcerative colitis (UC) (4 arms), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoints: Symptomatic remission at 12 weeks and Clinical remission at 52 weeks. Started Sep 2024; status: recruiting.
02
Drugs
nicotinamide
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06488625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06488625.